SDIX is a wholly owned subsidiary of OriGene Technologies, specializing in high quality, large-scale GMP antibody production in the U.S, Delaware and Maine.
For over 30 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers, world-wide, to meet high performance diagnostic and commercialization objectives. All sites are ISO 13485:2016 certified.
Products include critical reagents such as antibodies to Troponin I, Strep A, CRP, Apo A1, ApoB, Micro-albumin and Calibrators. SDIX’s services include Polyclonal Development and production in a variety of species as well as large-scale Monoclonal Antibody Production (ascites and in vitro).